A
Advanced Cancer Therapeutics
Advanced Cancer Therapeutics, LLC engages in the discovery, development, manufacture, and commercialization of cancer therapeutics
About Advanced Cancer Therapeutics
Advanced Cancer Therapeutics (ACT) is a privately held biotechnology company established in January 2007, operating out of Louisville, Kentucky. The firm was created to commercialize pioneering cancer research emerging from the University of Louisville's James Graham Brown Cancer Center. ACT operates on a distinctive business model built upon a strategic partnership with the Brown Cancer Center and the University of Louisville Research Foundation. This arrangement grants ACT exclusive worldwide licenses to novel cancer therapeutics discovered at the center under pre-negotiated terms, enabling the company to rapidly advance these discoveries toward pharmaceutical partnerships and eventual patient use.
The company was founded by key figures from the University of Louisville, including Dr. Donald M. Miller, a distinguished physician-scientist who served as Director of the Brown Cancer Center. Dr. Miller's extensive research background is in gene-targeted therapeutics and the development of oligonucleotide-based therapies, such as the DNA aptamer AS1411, which was the first of its kind to be tested in cancer patients. This scientific foundation is central to the company's mission. The initial leadership team included Randall B. Riggs, who was appointed President and CEO in January 2008. Riggs brought extensive corporate strategy and business development experience from his prior roles at pharmaceutical and biotech companies like Eli Lilly & Company, Lexicon Pharmaceuticals, and BioCryst Pharmaceuticals.
ACT’s primary business is the identification, licensing, and early-stage development of promising anti-cancer drug candidates. Its revenue model is centered on advancing these assets through preclinical and early clinical stages to a point where they can be partnered or out-licensed to larger pharmaceutical companies for late-stage development, commercialization, and manufacturing. A significant milestone for the company was advancing its first-in-class drug candidate, PFK-158, into Phase 1 human clinical trials. PFK-158 is a small molecule inhibitor of PFKFB3, a novel cancer metabolism target crucial for tumor growth. By inhibiting this target, the drug aims to prevent tumor cells in cancers like melanoma, lung, colon, and breast from using glucose as a fuel source. The company has also developed preclinical programs targeting Choline Kinase (CK), another enzyme over-expressed in many solid tumors.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANTOther financing | Oct 2012 | $158K | — | National Cancer Institute (NCI) | ↗ |
| SERIES A✓Equity / VC | Jul 2010 | $10M | $40M | Undisclosed | — |
Growth signals
Latest recorded traffic for Advanced Cancer Therapeutics is 290 monthly website visits, down 14.7% over the last three months. Advanced Cancer Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Advanced Cancer Therapeutics in the Louisville ecosystem
The Advanced Cancer Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Commonwealth Capital Ventures
National Cancer Institute (NCI)
Other known investors1 additional known investor
University of Louisville
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Advanced Cancer Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Advanced Cancer Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









